CIC
ABVC icon

Chase Investment Counsel’s ABVC BioPharma ABVC Stock Holding History

Chase Investment Counsel’s Portfolio ABVC Stock Details ABVC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-178,377
Closed -$233K – 122
2024
Q1 		$233K Buy
+178,377
New +$231K 0.09% 127

Other funds holding ABVC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APP
Avantax Planning Partners Dubuque, Iowa $3.64B AUM 14.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SAG
Spotlight Asset Group Oakbrook Terrace, Illinois $143M AUM 20.66% 1-Year Est. Return

Chase Investment Counsel's ABVC Position: Q2 2024 in Review

Chase Investment Counsel sold out of ABVC BioPharma (ABVC) in Q2 2024, closing a stake of 178,377 shares — an estimated $233K sold.

Chase Investment Counsel first reported a position in ABVC in Q1 2024 and held it in 1 quarter. The position peaked at $233K in Q1 2024. 11 funds tracked by Wall St. Rank hold ABVC as of Q2 2024.

  • Chase Investment Counsel reported no remaining ABVC BioPharma position as of Q2 2024 after selling out during the quarter.
  • Chase Investment Counsel sold 178,377 ABVC BioPharma shares in Q2 2024, an estimated $233K.
  • Chase Investment Counsel first reported a position in ABVC BioPharma in Q1 2024 and held it in 1 quarter.
  • Chase Investment Counsel's ABVC BioPharma position peaked at $233K in Q1 2024.
  • 11 funds tracked by Wall St. Rank held ABVC BioPharma as of Q2 2024.

Based on Chase Investment Counsel's 13F filing for Q2 2024, filed 2 Aug 2024.